Acuta Capital Partners’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-112,500
Closed -$2.7M 48
2019
Q3
$2.7M Sell
112,500
-369,000
-77% -$9.82M 1.95% 15
2019
Q2
$13.7M Buy
481,500
+100,000
+26% +$2.5M 4.88% 5
2019
Q1
$9.54M Sell
381,500
-61,000
-14% -$1.16M 4.54% 8
2018
Q4
$5.57M Sell
442,500
-650,000
-59% -$7.69M 4.25% 10
2018
Q3
$10.4M Sell
1,092,500
-1,567,710
-59% -$17.3M 3.72% 9
2018
Q2
$24.8M Sell
2,660,210
-657,790
-20% -$4.63M 4.42% 6
2018
Q1
$18.4M Buy
3,318,000
+22,889
+0.7% +$142K 3.01% 10
2017
Q4
$21.5M Hold
3,295,111
4.06% 6
2017
Q3
$28.9M Buy
3,295,111
+214,966
+7% +$1.75M 5.18% 5
2017
Q2
$25.7M Sell
3,080,145
-3,414
-0.1% -$27.8K 7.18% 4
2017
Q1
$28.3M Sell
3,083,559
-429,602
-12% -$3.52M 6.71% 3
2016
Q4
$27.2M Buy
3,513,161
+368,512
+12% +$2.76M 10.11% 1
2016
Q3
$23.9M Sell
3,144,649
-42,958
-1% -$243K 8.99% 2
2016
Q2
$16M Buy
3,187,607
+450,965
+16% +$2.42M 7.71% 2
2016
Q1
$14.8M Buy
2,736,642
+1,020,642
+59% +$6.04M 8.26% 2
2015
Q4
$12.4M Buy
1,716,000
+811,000
+90% +$5.46M 5.91% 4
2015
Q3
$4.24M Buy
905,000
+106,900
+13% +$1.02M 2.46% 11
2015
Q2
$8.89M Buy
+798,100
New +$7.86M 5.5% 3
2015
Q1
Sell
-29,024
Closed -$280K 63
2014
Q4
$280K Buy
+29,024
New +$227K 0.19% 60

Other funds holding VCYT

Acuta Capital Partners's VCYT Position: Q4 2019 in Review

Acuta Capital Partners sold out of Veracyte (VCYT) in Q4 2019, closing a stake of 112,500 shares — an estimated $2.7M sold.

Acuta Capital Partners first reported a position in VCYT in Q4 2014 and held it in 19 quarters. The position peaked at $28.9M in Q3 2017. 179 funds tracked by Wall St. Rank hold VCYT as of Q4 2019.

  • Acuta Capital Partners reported no remaining Veracyte position as of Q4 2019 after selling out during the quarter.
  • Acuta Capital Partners sold 112,500 Veracyte shares in Q4 2019, an estimated $2.7M.
  • Acuta Capital Partners first reported a position in Veracyte in Q4 2014 and held it in 19 quarters.
  • Acuta Capital Partners's Veracyte position peaked at $28.9M in Q3 2017.
  • 179 funds tracked by Wall St. Rank held Veracyte as of Q4 2019.

Based on Acuta Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.